Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an ...

while Eli Lilly’s stock has surged by 24% during the same period. On 21 December of last year, the Danish pharmaceutical company experienced a 21% plunge in its share price following ...

UnitedHealth Group CEO says complex US healthcare system needs to change Eli Lilly's stock tumbled 8% on Tuesday ... fails to impress in study; shares plunge Reuters, the news and media division ...

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

With its 2-star rating, we believe Eli Lilly’s stock is over-valued compared to our long-term fair value estimate. We are maintaining our Eli Lilly fair value estimate at $580. Mounjaro and ...

If any pharmaceutical producer is going to exploit the full potential of such medications, it's the well-capitalized Eli Lilly. I would even consider it to be a leading healthcare stock ...

See the 10 stocks » Below, I'm going to dive into what caused Lilly's stock to drop earlier this week and assess if the current price action is a good opportunity to buy the dip. What caused Eli ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%.